IV Golimumab efficacy and Early (ED) vs Late (LD) AS ⭐️ED better response than LD with PRO ⭐️Treatment-emergent adverse events/ serious adverse 🔼 LD as compared to ED Abst #0912 #ACR21 @RheumNow https://t.co/5EaWAvfQ57